Results 1 to 10 of about 96,616 (241)

Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies [PDF]

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023
Background We aimed to determine the proportion of highly active multiple sclerosis patients under high-efficacy therapies (HETs) achieve no evidence of disease activity-3 (NEDA-3) at 1 and 2 years, and to identify factors associated with failing to meet
Ricardo Alonso, Magdalena Casas, Luciana Lazaro, Nora Fernandez Liguori, Cecilia Pita, Leila Cohen, Juan Ignacio Rojas, Agustín Pappolla, Liliana Patrucco, Edgardo Cristiano, Marcos Burgos, Carlos Vrech, Raul Piedrabuena, Lopez Pablo, Norma Deri, Geraldine Luetic, Jimena Miguez, Mariela Cabrera, Alejandra Martinez, Gisela Zanga, Verónica Tkachuk, Santiago Tizio, Edgar Carnero Contentti, Eduardo Knorre, Felisa Leguizamon, Carolina Mainella, Pedro Nofal, Susana Liwacki, Javier Hryb, Maria Menichini, Claudia Pestchanker, Marina Alonso, Orlando Garcea, Berenice Silva   +33 more
doaj   +3 more sources

Increase of CSF inflammatory profile in a case of highly active multiple sclerosis [PDF]

BMC Neurology, 2019
Background Clinical and imaging follow-up coupled with cerebrospinal fluid (CSF) and possibly serum profiling could provide information on disease activity and disability evolution in multiple sclerosis patients. Case presentation We describe the case of
R. Magliozzi, D. Marastoni, S. Rossi, M. Castellaro, V. Mazziotti, M. Pitteri, A. Gajofatto, S. Monaco, M. D. Benedetti, M. Calabrese   +9 more
doaj   +5 more sources

Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis [PDF]

Neurology and Therapy
Introduction People with highly active multiple sclerosis benefit from early treatment with highly efficacious disease-modifying therapies. Here we present data on the efficacy of ublituximab versus teriflunomide in a subgroup of participants with highly
Hans-Peter Hartung, Derrick Robertson, Lawrence Steinman, Douglas L. Arnold, Peiqing Qian, Sibyl Wray, Edward Fox, Christopher A. Garner, Yihuan Xu, Koby Mok, Anne Gocke, Bruce A. C. Cree, Enrique Alvarez   +12 more
doaj   +4 more sources

Early clinical effect of cladribine in patients with highly active multiple sclerosis in Mexico [PDF]

Multiple Sclerosis Journal - Experimental, Translational and Clinical
Background Cladribine shows efficacy in multiple sclerosis (MS), but Latin American (LATAM) real-world data is limited, despite potential sociodemographic variations.
Sergio Sauri-Suarez, Sandra Quiñones, Manuel De la Maza-Flores, Arturo Marin-Contreras, Gil Playas-Pérez, Brenda Bertado-Cortes, Francisco Frias-Marquez, Gilberto Zuñiga-García, Francisco Rodriguez-Leal, Carlos Blaisdell-Vidal, Enrique Gomez-Figueroa   +10 more
doaj   +4 more sources

Are highly active and aggressive multiple sclerosis the same entity?

Frontiers in Neurology, 2023
Jorge Correale, Jorge Correale, Carolina A. Rush, Andrés Barboza   +3 more
doaj   +5 more sources

Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis [PDF]

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019
We evaluated the occurrence of infusion-associated reactions, severe adverse events and no evidence of disease activity 3 status of a therapeutic course consisting of natalizumab followed by alemtuzumab in paediatric-onset multiple sclerosis.
Monica Margoni, Francesca Rinaldi, Silvia Miante, Silvia Franciotta, Paola Perini, Paolo Gallo   +5 more
doaj   +3 more sources

Neurofibromatosis Type 1 with Highly Active Relapsing-Remitting Multiple Sclerosis (RRMS)

European Journal of Case Reports in Internal Medicine, 2021
Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disease which confers an increased risk of malignant tumour development. Relapsing remitting multiple sclerosis (RRMS) is an inflammatory demyelinating disease of the central nervous ...
Silvia Ciotti, Antonella Cometa, Claudia De Carlo, Giancarlo Martini, Andrea Marona, Laura Filippetti, Diego Carducci, Silvano Baratta, Mauro Zampolini, Francesco Corea   +9 more
doaj   +4 more sources

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center

Frontiers in Neurology, 2021
Background: Natalizumab (NTZ) and fingolimod (FTY) are second-line disease modifying treatments (DMTs) approved for Relapsing – Remitting Multiple Sclerosis (RRMS).
Marina Boziki, Christos Bakirtzis, Virginia Giantzi, Styliani-Aggeliki Sintila, Stylianos Kallivoulos, Theodora Afrantou, Ioannis Nikolaidis, Panagiotis Ioannidis, Theodoros Karapanayiotides, Ioanna Koutroulou, Dimitrios Parissis, Nikolaos Grigoriadis   +11 more
doaj   +3 more sources

Results of a study of the quality of life in patients with highly active multiple sclerosis in Russia

Неврология, нейропсихиатрия, психосоматика, 2022
Multiple sclerosis (MS) is a chronic autoimmune inflammatory demyelinating and neurodegenerative disease of the central nervous system. Now 2.8 million people in the world suffer from MS, since 2000 every 5 years there has been an increase in the number ...
A. N. Boiko, K. Z. Bakhtiyarova, M. A. Sherman, Z. A. Goncharova, I. V. Smagina, T. I. Khaibullin, N. N. Babicheva, N. N. Spirina, I. A. Yampolskaya-Gosteva, I. A. Sokolova, I. V. Greshnova, V. E. Nikitenkova, I. G. Lukashevich, A. V. Inzhinova, N. A. Malkova, D. S. Korobko, O. V. Boyko, I. S. Lozovskaya   +17 more
doaj   +2 more sources

Experience with cladribine tablets for highly active multiple sclerosis in real clinical practice

Неврология, нейропсихиатрия, психосоматика, 2022
Objective: to evaluate the efficacy and safety of cladribine tablets as a treatment for immune reconstitution of highly active multiple sclerosis (HAMS) in general clinical practice.Patients and methods.
S. V. Petrov, O. V. Boyko, A. N. Boyko
doaj   +3 more sources